Business Context and Reporting Period
This Form 8-K is filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on November 13, 2018. The report covers the fiscal third quarter and nine months ended September 30, 2018. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the third quarter and nine months ended September 30, 2018. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Operational Updates
- Regulatory Milestone: The U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug Application (IND) to initiate Phase III trials of MicroStat for mydriasis.
- Financial Reporting: The Company announced its financial results for the period ended September 30, 2018, though specific comparative data is not included in this summary text.
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future performance, or a detailed risk factor section within the text provided. The primary focus is the regulatory acceptance of the Phase III trial application. The Company notes that information in Item 2.02 is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash position figures in the attached Exhibit 99.1 press release.
- Confirm the timeline and specific design of the Phase III trials for MicroStat following the FDA IND acceptance.
- Review the Company's cash runway and funding requirements given the transition to Phase III trials.
- Check for any subsequent filings regarding the status of the MicroStat trials or updated financial guidance.